Mycophenolate mofetil: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett (→Uses) |
||
| Line 7: | Line 7: | ||
Mycophenolate mofetil is approved by the [[Food and Drug Administration]] in the [[United States]] for: | Mycophenolate mofetil is approved by the [[Food and Drug Administration]] in the [[United States]] for: | ||
* "prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants" | * "prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants" | ||
Mycophenolate mofetil has been studied for off label uses for: | |||
* Induction therapy for [[lupus nephritis]]<ref name="pmid16306519">{{cite journal| author=Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT et al.| title=Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. | journal=N Engl J Med | year= 2005 | volume= 353 | issue= 21 | pages= 2219-28 | pmid=16306519 | doi=10.1056/NEJMoa043731 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16306519 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16646618 Review in: ACP J Club. 2006 May-Jun;144(3):74] </ref> | |||
* Maintenance therapy for [[lupus nephritis]]<ref name="pmid22087680">{{cite journal| author=Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D et al.| title=Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. | journal=N Engl J Med | year= 2011 | volume= 365 | issue= 20 | pages= 1886-95 | pmid=22087680 | doi=10.1056/NEJMoa1014460 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22087680 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 21:59, 27 November 2012
In immunology, mycophenolate mofetil (brand name Cellcept) is an immunosuppressive agent.
History
Cellcept brand of mycophenolate mofetil was approved for Roche Palo by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 1995.[1] A generic version with a AB Therapeutic Equivalence Code was approved for Sandoz with a Abbreviated New Drug Application (ANDA) in 2008.[2]
Uses
Mycophenolate mofetil is approved by the Food and Drug Administration in the United States for:
- "prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants"
Mycophenolate mofetil has been studied for off label uses for:
- Induction therapy for lupus nephritis[3]
- Maintenance therapy for lupus nephritis[4]
References
- ↑ Anonymous. Drugs@FDA for FDA Application No. 050722. U S Food and Drug Administration
- ↑ Anonymous. Drugs@FDA for FDA Application No. 065379. U S Food and Drug Administration
- ↑ Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT et al. (2005). "Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.". N Engl J Med 353 (21): 2219-28. DOI:10.1056/NEJMoa043731. PMID 16306519. Research Blogging. Review in: ACP J Club. 2006 May-Jun;144(3):74
- ↑ Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D et al. (2011). "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.". N Engl J Med 365 (20): 1886-95. DOI:10.1056/NEJMoa1014460. PMID 22087680. Research Blogging.